Christopher Sumey

3.5k total citations
17 papers, 482 citations indexed

About

Christopher Sumey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Christopher Sumey has authored 17 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Christopher Sumey's work include Cancer Immunotherapy and Biomarkers (8 papers), Prostate Cancer Treatment and Research (6 papers) and Immunotherapy and Immune Responses (4 papers). Christopher Sumey is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Prostate Cancer Treatment and Research (6 papers) and Immunotherapy and Immune Responses (4 papers). Christopher Sumey collaborates with scholars based in United States, Australia and Japan. Christopher Sumey's co-authors include Marileila Varella‐Garcia, Ana B. Oton, Andrew Weickhardt, Anna E. Barón, Robert C. Doebele, Wilbur A. Franklin, D. Ross Camidge, Xian Lu, Dara L. Aisner and Paul A. Bunn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Christopher Sumey

16 papers receiving 477 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Sumey United States 7 387 292 100 91 69 17 482
Cláudia Casanova Italy 9 273 0.7× 267 0.9× 50 0.5× 100 1.1× 31 0.4× 24 421
Nooshin Hashemi Sadraei United States 10 199 0.5× 66 0.2× 63 0.6× 130 1.4× 49 0.7× 30 321
Jiewen Peng China 10 206 0.5× 103 0.4× 73 0.7× 53 0.6× 19 0.3× 19 331
Virginia Palomar Coloma France 4 421 1.1× 190 0.7× 20 0.2× 42 0.5× 72 1.0× 5 481
Junmiao Wen China 11 124 0.3× 209 0.7× 38 0.4× 50 0.5× 15 0.2× 33 336
J-P. Machiels Belgium 8 197 0.5× 84 0.3× 102 1.0× 78 0.9× 24 0.3× 16 394
Linpeng Zheng China 10 207 0.5× 150 0.5× 32 0.3× 77 0.8× 10 0.1× 17 304
Wenxiao Jia China 10 219 0.6× 157 0.5× 25 0.3× 95 1.0× 9 0.1× 25 374
Xiao Hu China 9 127 0.3× 118 0.4× 40 0.4× 77 0.8× 11 0.2× 33 267
Timothy Craig Allen United States 10 79 0.2× 290 1.0× 30 0.3× 78 0.9× 13 0.2× 14 401

Countries citing papers authored by Christopher Sumey

Since Specialization
Citations

This map shows the geographic impact of Christopher Sumey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Sumey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Sumey more than expected).

Fields of papers citing papers by Christopher Sumey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Sumey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Sumey. The network helps show where Christopher Sumey may publish in the future.

Co-authorship network of co-authors of Christopher Sumey

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Sumey. A scholar is included among the top collaborators of Christopher Sumey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Sumey. Christopher Sumey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Danila, Daniel C., C-C. Lin, Jia-Lin Lee, et al.. (2024). 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig. Annals of Oncology. 35. S971–S972. 1 indexed citations
4.
Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S1576–S1576. 1 indexed citations
5.
Powell, Steven, Jonathan Bleeker, Christopher Sumey, et al.. (2023). Expanding rural access to phase I clinical trials.. Journal of Clinical Oncology. 41(16_suppl). e18525–e18525. 1 indexed citations
6.
Dumbrava, Ecaterina E., Christopher T. Chen, Gregory M. Coté, et al.. (2023). Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). Molecular Cancer Therapeutics. 22(12_Supplement). B034–B034. 1 indexed citations
7.
Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S953–S954. 8 indexed citations
8.
Danila, Daniel C., David Waterhouse, Leonard J. Appleman, et al.. (2022). A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(16_suppl). TPS5101–TPS5101. 7 indexed citations
9.
10.
Kelly, William Kevin, David Pook, Leonard J. Appleman, et al.. (2021). Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). TPS183–TPS183. 3 indexed citations
11.
Bleeker, Jonathan, Christopher Sumey, Steven Powell, et al.. (2020). Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program. Surgery Open Science. 2(4). 25–31. 1 indexed citations
12.
Powell, Steven, Kathryn A. Gold, Christopher Sumey, et al.. (2020). Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. Journal of Clinical Oncology. 38(21). 2427–2437. 85 indexed citations
13.
Kelly, William K., Daniel C. Danila, William J. Edenfield, et al.. (2020). Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). TPS5589–TPS5589. 7 indexed citations
14.
15.
Powell, Steven, Christopher Sumey, John T. Reynolds, et al.. (2017). Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).. Journal of Clinical Oncology. 35(15_suppl). 6011–6011. 38 indexed citations
16.
Doebele, Robert C., Xian Lu, Christopher Sumey, et al.. (2012). Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer. Cancer. 118(18). 4502–4511. 223 indexed citations
17.
Sumey, Christopher & Thomas W. Flaig. (2010). Adjuvant medical therapy for prostate cancer. Expert Opinion on Pharmacotherapy. 12(1). 73–84. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cláudia Casanova Breakdown of academic impact, for papers by Nooshin Hashemi Sadraei Breakdown of academic impact, for papers by Jiewen Peng Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Junmiao Wen Breakdown of academic impact, for papers by J-P. Machiels Breakdown of academic impact, for papers by Linpeng Zheng Breakdown of academic impact, for papers by Wenxiao Jia Breakdown of academic impact, for papers by Xiao Hu Breakdown of academic impact, for papers by Timothy Craig Allen
Rankless by CCL
2026